Sector revisions Formycon AG

Equities

Market Closed - Xetra Other stock markets 16:35:16 10/02/2026 GMT			5-day change	1st Jan Change
23.50 ^EUR	+1.08%		+2.84%	-8.20%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Visibility	Nbr of analysts
FORMYCON AG		7
LONZA GROUP AG		23
BEONE MEDICINES AG		24
CELLTRION, INC.		22
IQVIA HOLDINGS INC.		20
REVOLUTION MEDICINES, INC.		19
MEDPACE HOLDINGS, INC.		12
EUROFINS SCIENTIFIC SE		15
IONIS PHARMACEUTICALS, INC.		22
ASCENDIS PHARMA A/S		16
ICON PUBLIC LIMITED COMPANY		16
QIAGEN N.V.		14
BIO-TECHNE CORPORATION		12
TEMPUS AI, INC.		12
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		15
ABIVAX		5
PRAXIS PRECISION MEDICINES, INC.		16
BLUEPRINT MEDICINES CORPORATION	-	-
HANGZHOU TIGERMED CONSULTING CO., LTD		11
Average		16
Weighted average by Cap.		19